An official website of the United States government
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Trial Status: closed to accrual
A global study to evaluate transarterial chemoembolization (TACE) in combination with
durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional
hepatocellular carcinoma
Inclusion Criteria
No evidence of extrahepatic disease
Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
Child Pugh score class A
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
Adequate organ and marrow function
Exclusion Criteria
History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
History of hepatic encephalopathy
Major portal vein thrombosis visible on baseline imaging
Uncontrolled arterial hypertension
Co-infection with HBV and HDV
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05301842.
